9 Amendments of Esther DE LANGE related to 2019/2816(RSP)
Amendment 23 #
Citation 18 a (new)
- having regard to several Member States' programmes such as the Netherlands Chain approach to reduce pharmaceutical residues in water;
Amendment 35 #
Recital B
B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas environmental concentrations are likely to increase as the population ages and grows, and climate change is expected to worsen the pollution of water by pharmaceutical residues as at times of drought concentrations will be higher; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;
Amendment 54 #
Recital E
E. whereas pharmaceuticals authorised for human use and put on the market before 2006 were not subject to an environmental risk assessment as part of the authorisation process and might therefore still lack such an assessment;
Amendment 63 #
Recital H
H. whereas the environmental impact of pharmaceuticals has been recognised as an issue of concern by a large number of international organisations, third countries, European institutions, industry associations and Non-Governmental Organisations; whereas some EU Member States such as the Netherlands, Germany and Sweden have already taken action to address the growing presence of pharmaceuticals in the environment;
Amendment 144 #
Paragraph 13 a (new)
13 a. Calls on Member States to include the issue of pharmaceuticals in the environment in their cross-border cooperation in river basins, and to coordinate measures where they are deemed useful;
Amendment 150 #
Paragraph 15
15. Calls on Member States and the Commission to support the development of pharmaceuticals intrinsically less harmful for the environment (‘greener pharmaceuticals’), which degrade more readily, into harmless substances, in wastewater treatment plants and the environment; taking into account that greater biodegradability could potentially impair the efficacy and shelf life of medicines, and make it harder to administer precise dosages;
Amendment 176 #
Paragraph 20
20. Points to the important role of procurement policy in promoting greener pharmaceuticals with low intrinsic toxicity for the environment; calls on the Commission to develop clear guidance on this issue;
Amendment 226 #
Paragraph 30
30. Calls for full enforcement of the existingon Member States to set up and enforce provisions with regard to take- back schemes for unused medicines;
Amendment 257 #
Paragraph 37
37. Recalls that pharmaceutical environmental information plays a key role for risk management and that this type of information should be transparent and made available to relevant stakeholders;